RxDoctor Payments Data

Maria Hafez, MD

Hospitalist · Charleston, WVNPI 1922449842

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $792 of the $1,057 with a category attached, or 74.9%. It is spread thinly across 11 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2023 at $543 and has fallen 72.5% since, to $149 in 2025. Among hospitalist clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,057in general payments, 2019–2025

Across 21 payments — averaging $50.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$218
  • Seagen Inc.$186
  • Gilead$125
  • Novocure Inc.$116
  • Eli Lilly$105
  • Amgen$100
  • plus $208 from 5 others
$125,310in research payments, 2019–2025

Across 10 payments — averaging $12,531 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$69K
  • Merck$35K
  • Pfizer$22K

What the payments were for

  • Food & beverage$79275%
  • Education$26525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057 in reported general payments places this provider in the 95th percentile of 110 hospitalist providers in West Virginia.

See all hospitalist providers in West Virginia

Medicare billing

Part B allowed, 2024
$24,196
Medicare patients
62
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib16$241,337
IbrancePalbociclib13$205,451
Anastrozole105$2,730
Exemestane16$2,492
Letrozole16$334
Gabapentin13$105
Ondansetron Hcl13$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$4$205,45113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 hospitalist providers in West Virginia.

Other hospitalist in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →